Medtronic SURTAVI Trial at the University of Rochester

The University of Rochester Medical Center has been selected to participate in a clinical trial to study treatment of aortic stenosis through transcatheter aortic valve implantation (TAVI) for patients with intermediate risk for surgical aortic valve replacement.

Why is this study being done?

The University of Rochester Medical Center is conducting this study to compare the results of TAVI using the Medtronic CoreValve to open-heart surgical aortic valve replacement in patients with severe symptomatic aortic stenosis who are considered at intermediate risk for traditional aortic valve surgery.

Who is eligible?

Patients eligible for this trial are people with severe aortic stenosis who are experiencing symptoms (difficulty breathing, chest pain or pressure, or fainting). The symptoms do not have to be severe but the degree of aortic stenosis does. These patients have intermediate risk for traditional aortic valve surgery.

What will the study entail?

You will be evaluated by our heart valve team. You will also need to undergo testing which may include echocardiograms, CT scans, blood work and pulmonary function testing.

The procedure involves placing a new catheter-mounted aortic valve into the position where the diseased valve is located. The existing valve will not actually be replaced; rather, the new valve will be placed inside the old valve and enlarge the opening.

How can I find out more?

To learn more about the Medtronic SURTAVI Trial at the University of Rochester Medical Center, please contact The Valve Clinic: Betsy Melito, ACNP-BC, valve clinic coordinator, at 585 275 0908 or send an email TAVI@urmc.rochester.edu.

Additional trial information @ http://clinicaltrials.gov/show/NCT01586910